Be a Smart Investor
Tuesday, August 8, 2017
Gemphire Therapeutics Inc. (GEMP) Dropped On Phase 2 Study Results
Gemphire Therapeutics Inc. (GEMP) announced results from its Phase 2b ROYAL-1 trial of oral gemcabene 600 mg Monday morning.
from RTT - Before the Bell http://ift.tt/2vfybdZ
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment